Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.

MMR protein and MLH1 methylation status predict the response to adjuvant therapy in endometrial cancer. The MMR system could be utilized for selection of patients who most likely benefit from adjuvant therapy.